Ionis to present at upcoming investor conferences
Get Alerts IONS Hot Sheet
Join SI Premium – FREE
- TD Cowen 44th Annual Health Care Conference on
Tuesday, March 5, 2024 - Stifel 2024 Virtual CNS Days on
Wednesday, March 20, 2024
A live webcast of these presentations can be accessed on the Investors & Media section of the Ionis website at https://ir.ionispharma.com/events-and-presentations/upcoming-events. Replays will be available on the Ionis website within 48 hours and will be archived for a limited time.
About Ionis Pharmaceuticals
For three decades, Ionis has invented medicines that bring better futures to people with serious diseases. Ionis currently has five marketed medicines and a leading pipeline in neurology, cardiology, and other areas of high patient need. As the pioneer in RNA-targeted medicines, Ionis continues to drive innovation in RNA therapies in addition to advancing new approaches in gene editing. A deep understanding of disease biology and industry-leading technology propels our work, coupled with a passion and urgency to deliver life-changing advances for patients. To learn more about Ionis, visit Ionispharma.com and follow us on X (Twitter) and LinkedIn.
View original content to download multimedia:https://www.prnewswire.com/news-releases/ionis-to-present-at-upcoming-investor-conferences-302072954.html
SOURCE Ionis Pharmaceuticals, Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FIGHT FOR CONTROL OF PROFITABLE WEST VIRGINIA POWER PLANT ESCALATES WITH MOTION TO DISMISS BANKRUPTCY
- InnoCare Announces Approval of Head-to-Head Registrational Phase III Trial of Mesutoclax with Azacitidine versus Venetoclax with Azacitidine in Treatment-Naive AML in China
- HelloNation Explains Collision Repair Choices With Insights From Auto Body Expert Carl Krause
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesRelated Entities
Stifel, Twitter, Cowen & CoSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share